clinical trial · NCT07591168
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
Sichuan Baili Pharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 92
Myelodysplastic SyndromesBL-M11D1
brief summary
This study is an open-label, multicenter, non-randomized Phase Ib/II clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BL-M11D1 for injection in patients with relapsed/refractory myelodysplastic syndromes.
started
May 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
May 15, 2026
detailed description
The study consists of two phases: a dose-exploration phase (Phase Ib) and a dose-expansion phase (Phase II).
official title
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-M11D1 for Injection in Patients With Relapsed/Refractory Myelodysplastic Syndromes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol